前列腺特异性膜抗原报告与数据系统1.0版与2.0版评估前列腺癌的比较
这项前瞻性多中心研究纳入443例前列腺癌男性患者,行68Ga-PSMA-11 PET/CT,分别用PSMA-RADS 1.0版和2.0版独立判读。2.0版在新诊断、生化复发和随访组的诊断准确率均优于1.0版;2.0版新增的5T分类改善了对治疗转移灶的刻画及其与PSA动态变化的相关性。
要点
- PSMA-RADS 2.0版在新诊断、生化复发和随访三组中的诊断准确率均高于1.0版。
- 2.0版对随访病例的敏感度提升明显(87.7% vs 95.7%)。
- 两版判读者间一致性相当,软组织评估一致性最低(ICC=0.36-0.50)。
核心结论
- PSMA-RADS 1.0版和2.0版对前列腺癌影像均高度准确和可靠,2.0版在随访和生化复发等困难病例中带来显著改善。
研究设计与样本
- 前瞻性多中心研究,2022年6月至2024年8月纳入443例前列腺癌男性(平均年龄68.6岁±8.1),行68Ga-PSMA-11 PET/CT,分新诊断组164例、生化复发组108例和随访组171例;由3名核医学放射科医师独立判读,病理和随访数据为参考标准。
关键影像表现/征象
- 2.0版新增PSMA-RADS 5T分类,增强了对治疗转移灶的刻画。
- 5T分类改善了与前列腺特异性抗原动态变化的相关性(rs=0.74 vs 0.61,P<.001)。
- 软组织评估的判读者间一致性最低(ICC=0.36-0.50)。
诊断标准与关键数值
- 2.0版 vs 1.0版诊断准确率:新诊断组97.4% vs 95.9%(P=.02)。
- 2.0版 vs 1.0版诊断准确率:生化复发组95.7% vs 92.6%(P=.004)。
- 2.0版 vs 1.0版诊断准确率:随访组94.7% vs 88.7%(P<.001)。
- 2.0版 vs 1.0版敏感度:随访组95.7% vs 87.7%(P<.001)。
- 2.0版 vs 1.0版治疗反应判别率:88.7% vs 82.3%(P=.02)。
临床应用与阅片要点
- 判读前列腺癌PSMA PET/CT时可采用PSMA-RADS 2.0版,其对随访和生化复发组的诊断准确率高于1.0版。
- 软组织病灶的判读者间一致性较低(ICC=0.36-0.50),报告时需注意。
- 2.0版5T分类有助于描述治疗后的转移灶并与PSA动态变化相关。
局限性
- 原文未报告局限性(原文结论未提及研究局限)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To assess diagnostic performance and reliability of Prostate-specific Membrane Antigen Reporting and Data System (PSMA-RADS) version 1.0 in evaluating prostate cancer (PCa) and compare it with the updated version (version 2.0). Materials and Methods This prospective, multicenter study was conducted between June 2022 and August 2024. Participants with PCa underwent gallium 68 (68Ga) PSMA-11 PET/CT imaging and were divided into three groups: new diagnoses, biochemical recurrence (BCR), and follow-up. Three nuclear medicine radiologists independently interpreted the images using PSMA-RADS version 1.0, followed by a retrospective assessment using PSMA-RADS version 2.0. Diagnostic performance was calculated using linear mixed-model analysis. Histopathology and follow-up data served as reference standards. Interrater agreement was evaluated using the intraclass correlation coefficient (ICC). Results The study included 443 male participants (mean age, 68.6 years ± 8.1 [SD]) divided into new diagnoses (n = 164), BCR (n = 108), and follow-up (n = 171) groups. Compared with PSMA-RADS version 1.0, version 2.0 improved diagnostic accuracy in new diagnoses (95.9% vs 97.4%, P = .02), BCR (92.6% vs 95.7%, P = .004), and follow-up (88.7% vs 94.7%, P < .001). Sensitivity substantially improved in follow-up cases (87.7% vs 95.7%, P < .001). Interrater agreement was comparable between two versions, with lowest reliability in soft tissue evaluation (ICC = 0.36-0.50). Introduction of the PSMA-RADS 5T category to version 2.0 enhanced the characterization of treated metastases, improving correlation with prostate-specific antigen dynamics (rs = 0.74 vs 0.61, P < .001) and the discrimination of treatment response (88.7% vs 82.3%, P = .02). Conclusion Both PSMA-RADS versions 1.0 and 2.0 were highly accurate and reliable for PCa imaging, with version 2.0 offering significant improvements, particularly in challenging follow-up and BCR cases. Keywords: PET/CT, Urinary, Prostate, Neoplasms-Primary, Oncology, Comparative Studies, Prostate Cancer, PSMA-RADS, Diagnostic Performance, Reliability Clinical trial registration no.: NCT06359717 Supplemental material is available for this article. © RSNA, 2025.
引用
- Almalki YE, Basha MAA, Ali SA, et al. Comparison of Prostate-specific Membrane Antigen Reporting and Data System Version 1.0 versus 2.0 for Prostate Cancer Assessment. Radiol Imaging Cancer. 2025. PMID: 40377421. doi:10.1148/rycan.240390
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。